Campaign Response to Multiple Sclerosis Treatment - Fampridine

I have been following with interest the experiences of people who have been prescribed Fampridine. In particular, I have read of the experiences of some individuals who took Fampridine during clinical trials, only to see it withdrawn when the trial ended. 

Improving mobility and with-it people’s quality of life is something that I would expect those drawing up guidelines about the treatment of MS to prioritise. 

As I'm sure you are aware, the National Institute for Health and Care Excellence’s (NICE) is updating its guideline on multiple sclerosis, including to take account of new evidence on the effectiveness of Fampridine for treating mobility in people with multiple sclerosis, and this guidance is expected to be published in July 2022.

While this is ultimately a matter for NICE, I think it is important that NICE is aware of the strength of feeling about Fampridine and I am assured this is the case.

However, as a Member of Parliament, it is not my place to put pressure on NICE, given their non-political status and given that they are staffed by experts in their fields.

Thank you for taking the time to contact me – it is appreciated.

Yours sincerely,

Sally-Ann Hart MP